Cancer BiologybioRxivPreprint
CD200 immune checkpoint reversal at the site of tumor vaccine inoculation: A novel approach to glioblastoma immunotherapy
Z. Xiong, E. Ampudia-Mesias, G. E. Pluhar…·M. R. Olin
This paper demonstrates that a CD200 peptide inhibitor enhances immune response in glioblastoma by reversing tumor-induced immunosuppression and downregulating PD-1 receptors.
DOI 10.1101/726778